vs

Side-by-side financial comparison of Editas Medicine, Inc. (EDIT) and Simulations Plus, Inc. (SLP). Click either name above to swap in a different company.

Editas Medicine, Inc. is the larger business by last-quarter revenue ($24.7M vs $18.4M, roughly 1.3× Simulations Plus, Inc.). Simulations Plus, Inc. runs the higher net margin — 3.7% vs -22.7%, a 26.4% gap on every dollar of revenue. On growth, Simulations Plus, Inc. posted the faster year-over-year revenue change (-2.7% vs -19.2%). Over the past eight quarters, Editas Medicine, Inc.'s revenue compounded faster (366.9% CAGR vs 0.3%).

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

Simulations Plus, Inc. develops absorption, distribution, metabolism, excretion, and toxicity (ADMET) modeling and simulation software for the pharmaceutical and biotechnology, industrial chemicals, cosmetics, food ingredients, and herbicide industries. In September 2014, the company acquired Cognigen Corporation, a provider of clinical trial data analysis and consulting services.

EDIT vs SLP — Head-to-Head

Bigger by revenue
EDIT
EDIT
1.3× larger
EDIT
$24.7M
$18.4M
SLP
Growing faster (revenue YoY)
SLP
SLP
+16.5% gap
SLP
-2.7%
-19.2%
EDIT
Higher net margin
SLP
SLP
26.4% more per $
SLP
3.7%
-22.7%
EDIT
Faster 2-yr revenue CAGR
EDIT
EDIT
Annualised
EDIT
366.9%
0.3%
SLP

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
EDIT
EDIT
SLP
SLP
Revenue
$24.7M
$18.4M
Net Profit
$-5.6M
$676.0K
Gross Margin
59.1%
Operating Margin
-31.3%
3.9%
Net Margin
-22.7%
3.7%
Revenue YoY
-19.2%
-2.7%
Net Profit YoY
87.6%
228.2%
EPS (diluted)
$0.03
$0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EDIT
EDIT
SLP
SLP
Q4 25
$24.7M
$18.4M
Q3 25
$7.5M
$17.5M
Q2 25
$3.6M
$20.4M
Q1 25
$4.7M
$22.4M
Q4 24
$30.6M
$18.9M
Q3 24
$61.0K
$18.7M
Q2 24
$513.0K
$18.5M
Q1 24
$1.1M
$18.3M
Net Profit
EDIT
EDIT
SLP
SLP
Q4 25
$-5.6M
$676.0K
Q3 25
$-25.1M
$-681.0K
Q2 25
$-53.2M
$-67.3M
Q1 25
$-76.1M
$3.1M
Q4 24
$-45.4M
$206.0K
Q3 24
$-62.1M
$843.0K
Q2 24
$-67.6M
$3.1M
Q1 24
$-62.0M
$4.0M
Gross Margin
EDIT
EDIT
SLP
SLP
Q4 25
59.1%
Q3 25
56.4%
Q2 25
64.0%
Q1 25
58.5%
Q4 24
54.0%
Q3 24
36.6%
Q2 24
71.5%
Q1 24
72.2%
Operating Margin
EDIT
EDIT
SLP
SLP
Q4 25
-31.3%
3.9%
Q3 25
-325.4%
3.8%
Q2 25
-1440.6%
-364.5%
Q1 25
-1635.1%
12.1%
Q4 24
-152.2%
0.7%
Q3 24
-107649.2%
-6.2%
Q2 24
-14016.2%
10.1%
Q1 24
-5902.3%
24.3%
Net Margin
EDIT
EDIT
SLP
SLP
Q4 25
-22.7%
3.7%
Q3 25
-333.0%
-3.9%
Q2 25
-1487.8%
-330.6%
Q1 25
-1633.5%
13.7%
Q4 24
-148.3%
1.1%
Q3 24
-101870.5%
4.5%
Q2 24
-13178.8%
16.9%
Q1 24
-5458.1%
22.0%
EPS (diluted)
EDIT
EDIT
SLP
SLP
Q4 25
$0.03
$0.03
Q3 25
$-0.28
$-0.03
Q2 25
$-0.63
$-3.35
Q1 25
$-0.92
$0.15
Q4 24
$-0.55
$0.01
Q3 24
$-0.75
$0.04
Q2 24
$-0.82
$0.15
Q1 24
$-0.76
$0.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EDIT
EDIT
SLP
SLP
Cash + ST InvestmentsLiquidity on hand
$146.6M
$35.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$27.3M
$127.1M
Total Assets
$186.5M
$137.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EDIT
EDIT
SLP
SLP
Q4 25
$146.6M
$35.7M
Q3 25
$165.6M
$32.4M
Q2 25
$178.5M
$28.4M
Q1 25
$221.0M
$21.4M
Q4 24
$269.9M
$18.2M
Q3 24
$265.1M
$20.3M
Q2 24
$279.1M
$119.0M
Q1 24
$296.2M
$108.5M
Total Debt
EDIT
EDIT
SLP
SLP
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$57.4M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
EDIT
EDIT
SLP
SLP
Q4 25
$27.3M
$127.1M
Q3 25
$13.5M
$124.8M
Q2 25
$19.2M
$123.8M
Q1 25
$62.4M
$189.5M
Q4 24
$134.3M
$184.7M
Q3 24
$175.6M
$182.4M
Q2 24
$232.0M
$180.9M
Q1 24
$294.4M
$177.0M
Total Assets
EDIT
EDIT
SLP
SLP
Q4 25
$186.5M
$137.8M
Q3 25
$201.8M
$131.9M
Q2 25
$210.6M
$134.4M
Q1 25
$263.7M
$201.4M
Q4 24
$341.6M
$196.9M
Q3 24
$327.6M
$196.6M
Q2 24
$384.8M
$192.7M
Q1 24
$440.3M
$194.0M
Debt / Equity
EDIT
EDIT
SLP
SLP
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.43×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EDIT
EDIT
SLP
SLP
Operating Cash FlowLast quarter
$-36.4M
$4.2M
Free Cash FlowOCF − Capex
$-36.4M
FCF MarginFCF / Revenue
-147.3%
Capex IntensityCapex / Revenue
0.2%
0.0%
Cash ConversionOCF / Net Profit
6.26×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EDIT
EDIT
SLP
SLP
Q4 25
$-36.4M
$4.2M
Q3 25
$-30.8M
$5.6M
Q2 25
$-50.2M
$8.1M
Q1 25
$-47.8M
$5.7M
Q4 24
$-50.8M
$-1.3M
Q3 24
$-52.6M
$1.7M
Q2 24
$-57.1M
$5.7M
Q1 24
$-49.9M
$5.8M
Free Cash Flow
EDIT
EDIT
SLP
SLP
Q4 25
$-36.4M
Q3 25
$-31.3M
$5.3M
Q2 25
$7.8M
Q1 25
$-47.9M
$5.6M
Q4 24
$-51.3M
$-1.4M
Q3 24
$-55.5M
$1.6M
Q2 24
$-60.6M
$5.6M
Q1 24
$-51.7M
$5.4M
FCF Margin
EDIT
EDIT
SLP
SLP
Q4 25
-147.3%
Q3 25
-414.6%
30.5%
Q2 25
38.5%
Q1 25
-1028.6%
25.0%
Q4 24
-167.6%
-7.2%
Q3 24
-90998.4%
8.8%
Q2 24
-11804.3%
30.0%
Q1 24
-4558.9%
29.4%
Capex Intensity
EDIT
EDIT
SLP
SLP
Q4 25
0.2%
0.0%
Q3 25
5.7%
1.5%
Q2 25
0.0%
1.5%
Q1 25
2.4%
0.3%
Q4 24
1.8%
0.5%
Q3 24
4788.5%
0.1%
Q2 24
681.1%
0.6%
Q1 24
164.8%
2.4%
Cash Conversion
EDIT
EDIT
SLP
SLP
Q4 25
6.26×
Q3 25
Q2 25
Q1 25
1.84×
Q4 24
-6.18×
Q3 24
1.97×
Q2 24
1.81×
Q1 24
1.44×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EDIT
EDIT

Segment breakdown not available.

SLP
SLP

Services Segment$9.5M52%
Development$7.2M39%
Discovery$1.3M7%

Related Comparisons